Amgen’s T-VEC AdCom May Shed Light On How FDA Reviews Intralesional Immunotherapies
This article was originally published in The Pink Sheet Daily
FDA’s Oncologic Drugs and Cellular, Tissue and Gene Therapies advisory committees will weigh in on a new molecular entity in a nascent field of cancer vaccines April 29; could set precedent for other intralesional drug reviews.
You may also be interested in...
Amgen Amps Up T-VEC Story At ASCO With Filing Plans And Combos
Amgen will file the cancer immunotherapy talimogene laherparepvec for the treatment of metastatic melanoma later this year, although the product’s larger commercial potential likely lies om combination with other immunotherapies.
R&D Briefs: Alprolix Approval Bodes Well, T-VEC Stumbles, Curis Back On Track
FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.
Medicare Price Negotiations: Competitors’ Net Prices, Clinical Benefit Are ‘Starting Point’ For Initial Offer
CMS chose the prices of therapeutic alternatives and these competitors’ comparative benefits as the ‘foundation and starting point’ for setting an initial offer for drugs subject to negotiation, ahead of other factors Congress laid out it could consider that are more singularly focused on the specific drug at issue.